Health Technology Assessment of Oxazolidinones for MRSA-Associated Complicated Skin and Soft Tissue Infections
Drug Design, Development and Therapy · 2026-01 · Volume 20 · 1-18
DOI: 10.2147/dddt.s551561 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-01. Verfasst von Yucheng Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Oxazolidinones, Anti-Bacterial Agents, Soft Tissue Infections, Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People's Republic of China.
ORCID-Profile: Yucheng Zhao, Jisheng Chen
Zitieren
APA
Zhao, Y., Huang, B., Yang, Z., Kuang, H., & Chen, J. (2026). Health Technology Assessment of Oxazolidinones for MRSA-Associated Complicated Skin and Soft Tissue Infections. Drug Design, Development and Therapy, Volume 20, 1-18. https://doi.org/10.2147/dddt.s551561
Vancouver
Zhao Y, Huang B, Yang Z, Kuang H, Chen J. Health Technology Assessment of Oxazolidinones for MRSA-Associated Complicated Skin and Soft Tissue Infections. Drug Design, Development and Therapy. 2026;Volume 20:1-18. doi:10.2147/dddt.s551561
BibTeX
@article{Zhao2026,
author = {Zhao, Yucheng and Huang, Baisen and Yang, Zunchang and Kuang, Hongjie and Chen, Jisheng},
title = {Health Technology Assessment of Oxazolidinones for MRSA-Associated Complicated Skin and Soft Tissue Infections},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--18},
doi = {10.2147/dddt.s551561}
}
EUVIMED